Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zontivity

- PMLiVE

FDA panel rejects cardiovascular outcomes claim for Vytorin

Merck & Co fail to convince regulator's advisors

Projects selected for MSD-backed digital accelerator

Disease-specific mobile apps among those winning support from Velocity Health

- PMLiVE

Merck & Co posts positive hepatitis C data

Elbasvir/grazoprevir achieves high cure rates for patients who inject drugs

- PMLiVE

Merck seeks oasis in CETP inhibitor desert

Pledgesto continue anacetrapib trials despite series of failures in its class

- PMLiVE

Merck defeated in antibiotic patent case in US

Loses four patents protecting Cubicin from generic competition

- PMLiVE

At long last, Merck gets FDA panel backing for Bridion

Unanimous vote in favour of drug suggest it is back on course for approval

- PMLiVE

US government probes Lilly and Merck over drug pricing

Department of Justice investigates drug pricing with regard to Medicaid programme

- PMLiVE

Merck and MacroGenics collaborate on immuno-oncology

Evaluates margetuximab with Keytruda for gastric cancer

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

- PMLiVE

Keytruda ups survival in lung cancer, misses secondary target

Data shows Keytruda fails to beat BMS' Opdivo

Merck & Co reorganises its HCP communities, hands Univadis to Physicians Interactive

Physicians Interactive outlines globalambitions for its newly-expanded network

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links